Anders Malling Sørensen

Title: Innovations of Anders Malling Sørensen

Introduction

Anders Malling Sørensen is a notable inventor based in Kobenhavn V, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of short interfering RNA (siRNA) analogues. His work focuses on enhancing the therapeutic potential of RNA interference (RNAi) for various medical applications.

Latest Patents

Anders Malling Sørensen holds a patent for novel double-stranded short interfering (siRNA) analogues that comprise locked nucleic acid (LNA) monomers. This invention is designed to induce sequence-specific post-transcriptional gene silencing in many organisms. The siRNA analogues consist of a sense strand and an antisense strand, each containing 12-35 nucleotides. These compounds exhibit improved properties compared to non-modified siRNAs and may serve as therapeutic agents in the treatment of various forms of cancer.

Career Highlights

Anders is associated with Santaris Pharma A/S, a company that focuses on developing innovative RNA-targeted therapies. His work at Santaris Pharma has positioned him as a key figure in advancing RNAi technology and its applications in medicine.

Collaborations

Throughout his career, Anders has collaborated with notable colleagues such as Joachim Elmén and Claes Wahlestedt. These partnerships have contributed to the advancement of research in the field of RNA therapeutics.

Conclusion

Anders Malling Sørensen's contributions to the field of biotechnology, particularly through his patented siRNA analogues, highlight his role as an influential inventor. His work continues to pave the way for innovative therapeutic solutions in cancer treatment.